DDD Partners LLC Cuts Stock Position in Johnson & Johnson $JNJ

Key Points

• DDD Partners LLC reduced its stake in Johnson & Johnson by 10.2%, now holding 130,441 shares worth approximately $19.9 million as of the latest reporting period.
• Insider trading report shows EVP Jennifer L. Taubert sold 56,471 shares valued at over $10 million, reducing her ownership by 24.08%.
• Johnson & Johnson's recent earnings report indicated $2.26 EPS and a net margin of 27.26%, with analysts forecasting a 10.58 EPS for the current fiscal year.

DDD Partners LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,441 shares of the company's stock after selling 14,833 shares during the period. Johnson & Johnson makes up approximately 2.1% of DDD Partners LLC's investment portfolio, making the stock its 19th biggest position. DDD Partners LLC's holdings in Johnson & Johnson were worth $19,925,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Moment Partners LLC grew its position in shares of Johnson & Johnson by 0.8% during the second quarter. Moment Partners LLC now owns 9,653 shares of the company's stock valued at $1,475,000 after purchasing an additional 76 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Johnson & Johnson by 1.9% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,157,669 shares of the company's stock worth $940,584,000 after purchasing an additional 113,356 shares during the last quarter. West Michigan Advisors LLC lifted its stake in Johnson & Johnson by 38.9% in the second quarter. West Michigan Advisors LLC now owns 7,054 shares of the company's stock worth $1,077,000 after purchasing an additional 1,976 shares during the last quarter. Kathleen S. Wright Associates Inc. lifted its stake in Johnson & Johnson by 3.1% in the second quarter. Kathleen S. Wright Associates Inc. now owns 7,500 shares of the company's stock worth $1,225,000 after purchasing an additional 227 shares during the last quarter. Finally, Moloney Securities Asset Management LLC lifted its stake in Johnson & Johnson by 4.2% in the second quarter. Moloney Securities Asset Management LLC now owns 37,079 shares of the company's stock worth $5,664,000 after purchasing an additional 1,510 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $190.38 on Friday. The firm's fifty day simple moving average is $182.26 and its two-hundred day simple moving average is $166.13. The company has a current ratio of 1.07, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The firm has a market capitalization of $458.69 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is presently 50.19%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Daiwa Capital Markets raised shares of Johnson & Johnson from a "neutral" rating to an "outperform" rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. Argus set a $210.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.